Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389001 | 0.86 | ALDH1A1 (0.49) | PIK3CD | |
| SCHEMBL2384769 | 0.77 | USP2 (0.55) | — | |
| SCHEMBL18484254 | 0.76 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL3411888 | 0.74 | GAA (0.52) | PIK3CDPIK3CGPIK3CB | |
| SCHEMBL2387126 | 0.73 | KCNH2 (0.58) | — | |
| SCHEMBL2388522 | 0.73 | LRRK2 (0.60) | — | |
| SCHEMBL2389043 | 0.73 | GRK5 (0.53) | — | |
| SCHEMBL2386017 | 0.71 | MET (0.55) | — | |
| SCHEMBL3407270 | 0.71 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL21388508 | 0.70 | MET (0.75) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | PIK3CD 1039/4885PIK3CG 1036/4885PIK3CB 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.